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Abstract
Protozoan parasites belonging to genera Leishmania and Trypanosoma are the etiological agents of severe neglected
tropical diseases (NTDs) that cause enormous social and economic impact in many countries of tropical and sub-tropical
areas of the world. In our screening program for new drug leads from natural sources, we found that the crude extract of
the endophytic fungus Cochliobolus sp. (UFMGCB-555) could kill 90% of the amastigote-like forms of Leishmania
amazonensis and inhibit by 100% Ellman’s reagent reduction in the trypanothione reductase (TryR) assay, when tested at
20 mgm L
21. UFMGCB-555 was isolated from the plant Piptadenia adiantoides J.F. Macbr (Fabaceae) and identified based on
the sequence of the internally transcribed spacer (ITS) regions of its ribosomal DNA. The chromatographic fractionation of
the extract was guided by the TryR assay and resulted in the isolation of cochlioquinone A and isocochlioquinone A. Both
compounds were active in the assay with L. amazonensis, disclosing EC50 values (effective concentrations required to kill
50% of the parasite) of 1.7 mM (95% confidence interval=1.6 to 1.9 mM) and 4.1 mM (95% confidence interval=3.6 to
4.7 mM), respectively. These compounds were not active against three human cancer cell lines (MCF-7, TK-10, and UACC-62),
indicating some degree of selectivity towards the parasites. These results suggest that cochlioquinones are attractive lead
compounds that deserve further investigation aiming at developing new drugs to treat leishmaniasis. The findings also
reinforce the role of endophytic fungi as an important source of compounds with potential to enter the pipeline for drug
development against NTDs.
Citation: Campos FF, Rosa LH, Cota BB, Caligiorne RB, Teles Rabello AL, et al. (2008) Leishmanicidal Metabolites from Cochliobolus sp., an Endophytic Fungus
Isolated from Piptadenia adiantoides (Fabaceae). PLoS Negl Trop Dis 2(12): e348. doi:10.1371/journal.pntd.0000348
Editor: Serap Aksoy, Yale University School of Medicine, United States of America
Received June 9, 2008; Accepted November 18, 2008; Published December 16, 2008
Copyright:  2008 Campos et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by Conselho Nacional de Desenvolvimento Cientifico e Tecnolo ´gico (CNPq), Fundac ¸a ˜o de Amparo a ` Pesquisa do Estado de Minas
Gerais (FAPEMIG), and Oswaldo Cruz Foundation (PDTIS-FIOCRUZ). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: zani@cpqrr.fiocruz.br
Introduction
Protozoan parasites belonging to the genera Leishmania and
Trypanosoma (order Kinetoplastida, family Trypanosomatidae)
occurs in the tropical and sub-tropical areas of the world, where
they cause severe diseases with huge medical, social, and economic
impact to millions of people [1]. All diseases caused by these
parasites are among the Neglected Tropical Diseases (NTDs) listed
by the World Health Organization [1]. Different species of
Leishmania affects over 12 million people and puts over 350 million
people at risk in 88 countries; Trypanosoma cruzi infects approxi-
mately 8 million and puts 100 million at risk in Central and South
America, and T. brucei infects 60 million people in 36 sub-Saharan
African countries [2]. The drugs currently available to treat the
different forms of leishmaniasis and trypanosomiasis were
introduced many decades ago and have significant drawbacks,
especially in terms of efficacy, length of treatment, route of
administration, toxicity, and cost [2]. To complicate the situation,
there is no new drug being developed by the major pharmaceutical
industries for these diseases [3].
It is well known that plant-associated microorganisms produce a
variety of metabolites with novel structures and interesting
biological activities [4,5,6,7]. Indeed, some medicinal properties
and biological activities initially attributed to plant species were
found latter to be due to the secondary metabolites produced by
their endophytic microorganisms [8]. With the aim to discover
new drug leads for some NTDs, we have been bioprospecting the
Brazilian flora and mycota using bioassays which includes the
protozoan parasite Leishmania amazonensis and the enzyme
trypanothione reductase (TryR). This flavoenzyme is part of a
complex enzymatic system present in protozoans of the order
Kinetoplastida that help them to survive under oxidative stress [9].
More important, TryR was shown to be essential for the growth
and survival of these parasites, and was validated as a drug target
for the discovery and design of new leishmanicidal and
trypanocidal drugs [9,10,11,12]. In our bioprospecting program,
www.plosntds.org 1 December 2008 | Volume 2 | Issue 12 | e348we have prepared hundreds of extracts of endophytic fungi
isolated from plants growing in different Brazilian biomes
(unpublished results). The isolate UFMGCB-555, obtained from
Piptadenia adiantoides J.F. Macbr (Fabaceae), showed strong activity
in the assay with TryR and L. amazonensis and was chosen for
investigation aiming at its bioactive components. In this report we
describe the molecular taxonomic identification of UFMGCB-555
and the isolation and identification of two leishmanicidal
compounds from its extract.
Methods
Cultivation of the endophytic fungus UFMGCB-555
The endophytic fungus was isolated from Piptadenia adiantoides
J.F. Macbr (Fabaceae) and deposited at Colec ¸a ˜o de Microrga-
nismos e Ce ´lulas da Universidade Federal de Minas Gerais under
the code UFMGCB-555. The fungus was grown in potato
dextrose agar (PDA) medium for 5 days at 2862uC. Five
millimeter diameter plugs of this culture were then inoculated at
the center of 160 Petri dishes (90 mm diameter), each containing
20 mL of malt extract agar (MEA) medium (1% glucose, 1% malt
extract, 0.1% peptone, and 1.5% agar). The plates were incubated
at 2862uC for 14 days. After this period, a small aliquot of the
biomass was used for extraction of DNA and the remaining
material extracted with ethyl acetate for the isolation of the fungal
secondary metabolites. Five plates which were not inoculated with
the fungus were subjected to the same protocol to serve as control
of the culture medium.
Molecular identification of the fungus UFMGCB-555
The DNA was extracted according to the protocol described by de
Hoog [13]. The ribosomal DNA internal transcribed spacer domains
(rDNA-ITS) were amplified using the primers ITS1 (59-TCCG-
TAGG-TGAACCTGCGG-39) and ITS4 (59-TCCTCCG-
CTTATTGATATGC-39), as previously described [14]. Five
sequences were generated using MEGABACE (Amersham Biosci-
ences, USA) which were used to feed PHRED-PHRAP software [15]
in order to find the consensus sequence. The sequence thus obtained
was compared with those deposited in the GenBank using the
software BLASTn [16] to identify the fungus to the genus level. The
sequence was deposited in the GenBank (accession number
EU684269). Phylogenetic relationships were calculated using the
v e r s i o n4 . 0o ft h es o f t w a r eM E G A[ 1 7 ] .T h ep h y l o g e n e t i ct r e ew a s
constructed using the neighbor joining algorithm with bootstrap
values calculated from 1000 replicate runs. The Kimura 2-parameter
model [18] was used to estimate the evolutionary distances.
Extraction of secondary metabolites from the fungal
cultures
The fungus culture material from 160 Petri dishes (approxi-
mately 3 liters) was transferred to a six-liter Erlenmeyer containing
3.5 L of ethyl acetate and left in contact for 48 at room
temperature. After decantation, the organic phase was filtered
and the solvent evaporated under vacuum in a rotary-evaporator
at 45uC. Residual solvent was eliminated in a vacuum centrifuge at
40uC, and the crude extract thus obtained was stored at 240uC
until use. A similar extraction procedure was carried out using the
five plates containing medium only to generate a control extract of
the medium.
Chromatographic fractionation of the extract
Theinitialfractionationstep involved high-speed counter-current
chromatography (HSCCC), using a Pharma-Tech chromatograph
model CCC-1000 equipped with three multilayer coils totaling a
volume of 850 mL. With the rotor stopped, the coils were filled with
the lower aqueous phase of the biphasic mixture of hexane-ethyl
acetate-methanol-water (1.2:0.8:1:1). The coils were then rotated at
1000 r.p.m. and the upper phase was pumped at a flow-rate of
5m Lm i n
21 in tail-to-head direction until hydrodynamic equilib-
rium was reached, that is, until only the mobile phase was flowing
out of the column. Part of the extract (800 mg) was then dissolved in
10 mL of equal parts of the upper and lower phases of the biphasic
solvent mixture and this mixture injected into the column. A total of
158 fractions of 15 mL each was collected. They were pooled into
40 groups based on their similarity, as assessed by thin-layer
chromatography (TLC) on silica gel plates (Merck). Group 10 was
fractionated on reversed-phase high performance liquid chroma-
tography (HPLC) using a semi preparative column (250620 mm)
filled with RP-18 (octadecyl) silica gel with 5 mm average particle
size. The separation was run using a gradient of methanol-water
from 70 to 100% in 50 min, at a flow rate of 10 mL min
21.T h e
column effluent was monitored with a UV detector set at a
wavelength of 220 nm. Two pure compounds, 1 (14 mg) and 2
(2.4 mg) were isolated.
Spectral data of the isolated compounds
Proton (
1H) and carbon (
13C) nuclear magnetic resonance
(NMR) spectra (Figure S1), Distortionless Enhancement by
Polarization Transfer (DEPT), Heteronuclear Multiple-Quantum
Coherence (HMQC), and Heteronuclear Multiple Bond Correla-
tion (HMBC) experiments were run on a Bruker DRX 400
spectrometer using the pulse programs provided by the manufac-
turer. The substances were dissolved in perdeuterated solvents
containing 0.1% tetramethylsilane as the internal chemical shift
standard. The data obtained from these spectra are summarized in
the Tables 2–4. Mass spectra (MS) were acquired on a Thermo
Finnigan LCQ-Advantage spectrometer equipped with an electro-
spray ion (ESI) source. Solutions of the compounds at 200 mg
mL
21 in MeOH-H2O (1:1) were infused at 25 mL min
21, and the
Author Summary
Protozoans belonging to genera Leishmania and Trypano-
soma are single-cell organisms that can infect humans and
cause disfiguring lesions and debilitating or fatal diseases,
with enormous social and economic impact in many
tropical and sub-tropical areas of the world. The drugs
currently available to treat the different forms of leishman-
iasis and trypanosomiasis were introduced many decades
ago and have significant drawbacks, especially in terms of
efficacy, length of treatment, route of administration,
toxicity, and cost. In our screening program for new natural
products with leishmanicidal activity, we found that the
crude extract of a fungus living within the plant Piptadenia
adiantoides could kill 90% of the amastigote-like forms of
Leishmania amazonensis. The bioassay-guided fractionation
of the extract resulted in the isolation of cochlioquinone A
and isocochlioquinone A, which showed EC50 values
(effective concentrations required to kill 50% of the
parasite) of 1.7 mM and 4.1 mM, respectively. These
compounds were not active against three human cancer
cell lines (MCF-7/mammary, TK-10/renal, and UACC-62/
melanoma), indicating some degree of selectivity towards
the parasites. Our results suggest that cochlioquinones may
serve as starting points for developing new drugs to treat
leishmaniasis and reinforce the role of endophytic fungi as
an important source of natural products with relevant
biological activities.
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between 50 and 1000 daltons. The cone voltages were optimized
for positive and negative ion analysis in the range between 25 and
50 V. The capillary voltages were set at 4.5 kV in positive ion
mode and 23.1 kV in negative ion mode. In the MS/MS
experiments, the parent ion isolation width was 3.8 daltons and
the normalized collision energy was set at 30% for both
compounds 1. Fifty scans from 150 to 600 daltons were collected
to generate the averaged spectra.
Assays with recombinant trypanothione reductase from
Trypanosoma cruzi (TryR)
The TryR microtitre plate assay procedure based on in situ
Ellman’s-reagent-mediated regeneration of trypanothione, de-
scribed by Hamilton et al. [19], was used during the screening
and the bioassay-guided fractionation protocols. The assay was
performed in 96-well plates (Costar 9017, Corning, USA) using
Hepes buffer (40 mM, pH 7.5) with 1 mM EDTA. Each assay
well (250 mL) contained enzyme (1 mU), trypanothione (1 mM)
and NADPH (200 mM). The extracts, fractions and pure
compounds were added to the above mixture and incubated at
30uC during 30 min. After this period, Ellman’s reagent [5,59-
dithiobis(2-nitrobenzoic acid) –DTNB] was added (70 mM) and
the absorbance (Abs) measured at the wavelength of 412 nm in the
kinetic mode during the time (t) of 10 minutes at every 10 seconds.
The slope of the curve DAbs/Dt is proportional to DTNB
reduction which, in absence of competing reactions, is propor-
tional to the enzyme activity. The inhibition of the coupled system
was calculated as the ratio between slope DAbs/Dt) of the
experimental wells and that of the controls without drug, that is,
percent inhibition=[12slopeexp/slopecontr]6100.
The classical assay based on the measurement of NADPH
consumption was performed in 1 mL cuvettes (1 cm light path
length) at 27uC using a Beckman DU spectrophotometer. Each
cuvette contained 500 mL Hepes buffer (40 mM, pH 7.5),1 mM
EDTA, 4 mU enzyme, 200 mM NADPH, 50 mM cochlioquinone
A, and 100 mM trypanothione. The enzyme, NADPH and the
compound were pre-incubated for 5 minutes at 27uC. The
absorbance measurement at the wavelength of 340 nm was started
in the kinetic mode (1 reading per second) for about 30 seconds.
The sample compartment cover was opened during 3 to 4 seconds,
just enough for the quick addition of the substrate. After closing, the
absorbance measurement was continued for another 30 seconds.
The initial reaction velocity (v0) was calculated by the instrument
software using the first 5–20 data points after the substrate addition.
These points should fit a strait line with R
2 (squared correlation
coefficient) greater than 0.99. To estimate the effect of the
compound on enzyme activity, the v0 values obtained in the
experiments with and without cochlioquinone A were compared.
Each experiment was repeated three times.
Figure 1. Phylogenetic tree depicting the relationships between UFMGCB-555 and related species. The tree was constructed by
neighbor-joining analysis (Kimura-2 parameter) of their ITS domain sequences. Bootstrap percentage from 1000 replicates is shown. The GenBank
accession numbers are indicated for each reference sequence. The ITS sequence of Alternaria (AY673074) was used as an outgroup.
doi:10.1371/journal.pntd.0000348.g001
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The effect of the extract and isolated compounds on the survival
and growth of the human cancer cell lines UACC-62 (melanoma),
MCF-7 (breast), and TK-10 (renal), was determined using a
colorimetric method developed at the National Cancer Institute-
USA [20,21]. Briefly, the cells were inoculated in 96-well plates and
incubated at 37uC for 24 h in 5% CO2 atmosphere. The solutions
of the test samples were added to the culture wells to attain the
desired concentrations, and the plates incubated for further 48 h.
Trichloroacetic acid was added to each well to precipitate the
proteins, which were stained with sulforhodamine B. After washing
out the unbound dye, the stained protein was dissolved with 10 mM
Tris, and the absorbance measured at the wavelength of 515 nm.
Results were calculated using the absorbance measured in the test-
wells (T) in comparison with that of the control wells corresponding
totheinitial cellinoculum (Ti) and cellsgrown for48 h without drug
(Tf),usingtheformula:[(T2Ti)/(Tf2Ti)]6100.Thisformulaallows
the quantification of both growth inhibition (values between zero
and 100) and cell death (values smaller than zero). Each sample was
tested in duplicate in two independent experiments.
Assay with amastigote-like forms of Leishmania
(Leishmania) amazonensis
Promastigotes of L. amazonensis (strain IFLA/BR/196/PH-8)
were obtained from lesions of experimentally infected hamsters.
The parasites were incubated for 9 days at 26uC in Schneider’s
medium buffered at pH 7.2. The promastigotes were then
stimulated to differentiate into amastigote-like forms by rising the
incubation temperature to 32uC and lowering the pH of the
Figure 2. Flowchart illustrating the isolation of cochlioquinone A and isocochlioquinone A. The fractionation was guided by the bioassay
with the enzyme trypanothione reductase, in which the crude extracts, fractions, and isolated compounds were tested at 20 mgm L
21.
doi:10.1371/journal.pntd.0000348.g002
Table 1. Biological activities of crude extract, fraction, and
compounds isolated from Cochliobolus sp. (UFMGCB-555)
tested at a single dose of 20 mgm L
21.
Samples AMA
a TryR
b Cancer cell lines
c
UACC-62 MCF-7 TK-10
Crude extract 87639 9 626 2 622 67688 0 616
Group 10 nt
d 9965 22 2
16 0 659 9 64 22 2
27 0 62 22 2 2
aPercentage of death of amastigote-like forms of Leishmania (Leishmania)
amazonensis. Control drug: amphotericin B at 0.2 mgm L
21.
bPercentage inhibition of the enzyme trypanothione reductase. Clomipramine
at 6 mM was used as 50% inhibition control.
cCytocidal activity (percentage of death of human cancer cells relative to the
initial inoculum). Control drugs: etoposide at 16 mgm L
21 and colchicine at
8 mgm L
21.
dnot tested.
The values represent the mean6S.D. of at least 2 independent experiments.
The minus symbol (2) means inactive.
doi:10.1371/journal.pntd.0000348.t001
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parasites were in the amastigote-like forms. The parasite concen-
tration was adjusted to 1610
8 cells mL
21,a n d9 0mL added to each
well of 96-well plates, followed by 10 mL of the solutions containing
the samples and control drug (0.2 mgm L
21 Amphotericin B -
Fungisone Bristol-Myers Squibb, Brazil). The plates were incubated
at 32uC for 72 h and the number of parasites estimated using the
MTT (methyl thiazolyl tetrazolium)-based colorimetric assay [22].
The results were calculated from the measured absorbancies using
the formula [12(Absexp/Abscontr)]6100, which express the per-
centage ofparasite death inrelation to the controls without drug.All
samples were tested in duplicate and the experiments repeated at
Figure 3. Dose response curves for 1 (diamonds) and 2 (squares) in the assay with amastigote-like forms of L. amazonensis. The EC50
(effective concentration to kill 50% of the parasites) values were found to be 1.7 mM (95% confidence interval=1.5 to 1.9 mM) and 4.1 mM (95%
confidence interval=3.6 to 4.7 mM), respectively. The data in the plots are derived from at least two independent experiments.
doi:10.1371/journal.pntd.0000348.g003
Figure 4. ESI-MS-MS in the positive ion mode showing the main fragments generated by cochlioquinone A (panel A) and
isocochlioquinone A (panel B). Both compounds show sodiated quasi-molecular ion peaks [M+Na]
+ at 555 daltons and the loss of acetic acid (D
m/z=60 daltons) from the side chain. In addition, the hydroxyl group in the pyrane ring of cochlioquinone A is responsible for the observed loss of
water (D m/z=18 daltons).
doi:10.1371/journal.pntd.0000348.g004
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the EC50 (effective concentration to kill 50% of the parasites) were
run as above, using 1:2 serial dilutions of the test compounds to
reach the appropriate concentrations. The experiments were run in
duplicate and repeated at least once.
Assays with microorganisms
The antimicrobial activity of the samples was evaluated using the
following microorganisms: Candida albicans ATCC18804, C. krusei
ATCC2159, Staphylococcus aureus ATCC12600, Escherichia coli
ATCC25922 and Cryptococcus neoformans ATCC32608. The yeasts
were grown on agar Sabouraud (Difco) at 28uC for 24 h, and their
inocula were adjusted in saline solution to Mac Farland optical
density scale 1 [23] before seeding into plates containing agar
Sabouraud. The bacteria were grown in Brain Heart Infusion (BHI,
Difco) in 6-mL tubes, and their concentration adjusted to 10
3 to 10
4
cells mL
21 before inoculation into plates containing agar BHI. In
each plate, five clean filter-paper disks with 6 mm diameter were
placed equidistant from each other on the surface of the medium.
Solutions of the samples at 10 mg mL
21 were prepared in 1%
aqueous dimethyl sulfoxide (1% aq. DMSO). Five microliters of
these solutions, corresponding to 50 mg of the sample, were applied
to the paper disks, and the plates incubated at 37uC for a period of
24 to 48 h. Aqueous solutions of amphotericin B and chloram-
phenicol at 10 mg mL
-1 were used as positive controls for yeasts and
bacteria, respectively. Solvent control consisted of 1% aq. DMSO.
The sample was considered active if it caused a growth inhibition
halo around the disk to which it was applied.
Statistical analysis
The software GraphPad Prism version 4.03 was used to
calculate the EC50 values using the non-linear curve fitting of
two ore more independent experimental datasets to a four-
parameter logistic dose-response model. No constraints were
applied to the curve fitting calculations.
Results
Molecular identification of UFMGCB-555
A small aliquot (1 g) of the fungus culture was used to isolate the
fungal DNA for sequencing of the ITS domains. These sequences
were used for the taxonomic identification of the fungus and for
Table 2.
1H-NMR and HSQC spectral data of 1 and comparison with literature data for cochlioquinone A.
Position Cochlioquinone A
a 1
Chemical shifts Multiplicity and coupling constants Chemical shifts Multiplicity and coupling constants
1 0.88 (3H, t, J=7.0) 0.85 (3H, t, J=6.8)
2 1.35 (2H, *) 1.45 (1H, *)
1.08 (1H, *)
3 1.60 (1H, *) 1.49 (1H, *)
4 5.01 (1H, dd, J=7.5, 5.0) 4.92 (1H, dd, J=7.7, 5.1)
5 3.22 (1H, *) 3.37 (1H, dq, J=7.0, 5.1)
11 6.63 (1H, s) 6.63 (1H, s)
12 4.93 (1H, dd, J=10.0, 1.3) 4.94 (1H, d, J=10.6)
13 1.72 (1H, d, J=10.0) 1.72 (1H, d, J=10.6)
15 1.91 (1H, dt, J=13.3, 3.8) 1.91 (1H, dt, J=13.2, 3.9)
2.09 (1H, dt, J=13.3, 3.3) 2.08 (1H, dt, J=13.2, 3.5)
16 1.56 (1H, *) 1.54 (1H, *)
1.79 (1H, *) 1.79 (1H, *)
17 3.17 (1H, dd, J=12.5, 3.8) 3.17 (1H, dd, J=11.9, 3.5)
19 1.40 (1H, *) 1.40 (1H, *)
2.47 (1H, m) 2.47 (1H, m)
20 1.43 (1H, *) 1.43 (1H, *)
1.65 (1H, *) 1.64 (1H, *)
21 3.25 (1H,dd, J=12.5, 2.5) 3.25 (1H,dd, J=11.9, 2.8)
23 1.17 (3H, s) 1.16 (3H, s)
24 1.18 (3H, s) 1.18 (3H, s)
25 1.01 (3H, s) 1.01 (3H, s)
26 1.32 (3H, s) 1.32 (3H, s)
27 1.14 (3H, d, J=6.8) 1.12 (3H, d, J=7.0)
28 0.87 (3H, d, J=7.0) 0.84 (3H, d, J=7.5)
30 1.98 (3H, s) 2.05 (3H, s)
Spectra were recorded at 400 MHz in CDCl3.
adata from reference [28].
J=coupling constant in Hz.
*overlapping multiplet signal.
doi:10.1371/journal.pntd.0000348.t002
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fungus UFMGCB-555 was then identified to the genus level as
Cochliobolus sp. and showed a close phylogenetic relationship with
C. melinidis (Genebank access number AF452445), from which its
consensus sequence differs by only 2.7% (12 nucleotides, 70%
bootstrap value).
Extraction of secondary metabolites
The culture material (3 liters) yielded 2 g of the crude extract,
representing a yield of approximately 0.6 g L
21 of culture broth.
This extract showed activity in different bioassays (Table 1) when
tested at 20 mgm L
21, but was completely inactive against C.
albicans, C. krusei, S. aureus, E. coli and C. neoformans when tested at
50 mg per disk (data not shown). The extract of the control (sterile)
culture medium was not active in these assays.
Bioassay-guided fractionation of the extract
Approximately 800 mg of the crude extract was subjected to
counter-current chromatography in an HSCCC to afford 158
fractions, which were pooled into 40 groups (Figure 2). After
testing all groups in the TryR assay, only Group 10 and Groups
24–40 showed some activity. Groups 24–40 were not studied
further because they presented low masses and were constituted of
complex and instable mixtures of highly polar compounds.
Fraction 10 (100 mg) was further fractionated using reversed-
phase HPLC to yield compounds 1 (14 mg; 1.4% w/w of the
crude extract) and 2 (2.4 mg; 0.24% w/w of the crude extract).
Both compounds strongly inhibited the growth of amastigote-
like forms of L.( L.) amazonensis, with EC50 values (effective
concentration to kill 50% of the parasites) of 1.7 mM (95%
confidence interval=1.5 to 1.9 mM) and 4.1 mM (95% confidence
interval=3.6 to 4.7 mM), respectively (Figure 3). However, only 1
was active in the DTNB-coupled TryR assay. Furthermore, while
the crude extract was toxic to three human cancer cell lines used in
this work (MCF-7, TK-10, and UACC-62), neither Group 10 nor
compounds 1 and 2 showed activity against these lineages
(Table 1). The compounds were also inactive against the five
pathogenic microorganisms investigated (data not shown).
Structure elucidation of the bioactive compounds
The electrospray ionization mass spectra (ESI-MS) of both
compounds exhibited quasi-molecular sodiated ion peaks
[M+Na]
+ with m/z 555 daltons in positive ion mode, and [M-
H]
2 with m/z 531 daltons in negative ion mode, indicating they
Table 3.
1H-NMR and HSQC spectral data of 2 and comparison with literature data for isocochlioquinone A.
Position Isocochlioquinone A
a 2
Chemical shifts Multiplicities and coupling constants Chemical shifts Multiplicities and coupling constants
1 0.89 (3H, t, J=7.0) 0.83 (3H, t, J=7.4)
2 1.25 (2H, *) 1.45 (1H, *)
1.08 (1H, *)
3 1.63 (1H, *) 1.56 (1H, *)
4 5.18 (1H, dd, J=7.5, 5.0) 5.04 (1H, dd, J=7.6, 5.3)
5 3.46 (1H, qnt, J=7.0) 3.37 (1H, dq, J=7.0, 5.3)
11 6.40 (1H, s) 6.52 (1H, s)
13 2.77 (1H, s) 2.78 (1H, s)
15 2.06 (1H, *) 2.08 (2H, *)
2.09 (1H, dt, J=13.3, 3.3)
16 1.60 (1H, *) 1.66 (1H, *)
1.80 (1H, *) 1.81 (1H, ddd, J=13.4, 7.33, 3.8)
17 3.16 (1H, dd, J=12.0, 3.8) 3.15 (1H, dd, J=11.9, 3.8)
19 1.30 (2H, *) 1.29 (1H, m)
2.75 (1H, *) 2.75 (1H, m)
20 1.60 (1H, *) 1.46 (1H, *)
1.74 (1H, *)
21 3.27 (1H,dd, J=12.5, 2.5) 3.26 (1H,dd, J=12.0, 2.9)
23 1.19 (3H, s) 1.19 (3H, s)
24 1.19 (3H, s) 1.19 (3H, s)
25 1.13 (3H, s) 1.01 (3H, s)
26 1.46 (3H, s) 1.48 (3H, s)
27 1.20 (3H, d, J=7.0) 1.19 (3H, d, J=7.0)
28 0.88 (3H, d, J=6.8) 0.86 3H, d, J=6.6
30 1.93 (3H, s) 2.05 (3H, s)
Spectra were recorded at 400 MHz in CDCl3.
adata from reference [28].
J=coupling constants in Hz.
*overlapping multiplet signal.
doi:10.1371/journal.pntd.0000348.t003
Leishmanicidal Metabolites from Cochliobolus sp.
www.plosntds.org 7 December 2008 | Volume 2 | Issue 12 | e348both have molecular weight of 532 g mol
21 (Figure 4). The peak
integration areas in the
1H NMR spectra (Table 2 and Table 3,
Figure S1) indicated the presence of 44 hydrogen atoms, while the
13C NMR spectra (Table 4) showed 30 signals for each compound.
Edited DEPT sub-spectra showed signals due eight methyl groups,
one belonging to an acetyl group, and five methylene carbon
atoms for both compounds. Signals due to eight methyne carbon
atoms, four of them oxygenated, were observed for compound 1,
while seven signals of methyne carbon atoms, three of them
oxygenated, were detected for in the spectra of compound 2.
Altogether, these data is compatible with the molecular formula
C30H44O8, with an index of hydrogen deficiency of 18,
corresponding to 9 unsaturations. The analysis of the
1H and
13C spectra allow to infer that both compounds have five double
bonds in their structures, with the remaining unsaturations
attributed to the presence of four rings. A quinonoid ring in 1
was suggested by the presence of the signals at 181.64 and 188.86
d, attributed to carbonyl groups, together with four signals
between 134.32 and 151.40 d in the
13C NMR spectrum. A
phenol moiety in 2 was indicated by the presence of six signals
between 107.0 and 181.5 d in the
13C NMR spectrum. A signal at
198.5 d suggested the presence of a ketone carbonyl in 2. The
connections between carbon and hydrogen atoms in the structures
were established based on the analysis of the two-dimensional
NMR experiments (COSY, HMQC and HMBC - Table 2 and
Table 3). The spectral data of 1 and 2 are in agreement with those
published in the literature for cochlioquinone A and isocochlio-
quinone, respectively (Figure 5).
Discussion
Several endophytic fungi were isolated from the P. adiantoides,a
plant species selected due to the activity of its extract in a panel of
assays used to screen the Brazilian flora for bioactive natural
products (unpublished results). Among the fungi isolated from this
plant, the isolate UFMGCB-555 showed strong activity in the
assays with TryR and L. amazonensis. Using molecular taxonomy
techniques, we were able to identify this fungus as Cochliobolus sp.
(Pleosporaceae, Ascomycota). This genus comprises approximately
50 species occurring all over the world [24], many of which can
parasitize plants and cause considerable agricultural losses [25].
Some species of Bipolaris, the anamorphic state of Cochliobolus, are
also the etiologic agent of several human diseases, such as sinusitis,
ocular infections, peritonitis, and meningoencephalitis [26,27].
However, in the present work we looked for the ability of
Cochliobolus UFMGCB-555 to produce secondary metabolites with
biological or pharmaceutical potential, especially for neglected
tropical diseases.
To guide the fractionation process aiming at the isolation of the
active compounds of this extract, we decided to use the TryR assay
developed by Hamilton et al. [19]. Besides being more economic
due to low consumption of the expensive substrate trypanothione,
this assay is simpler, safer and faster to perform than the assay with
L. amazonensis. Thus, the bioassay with the parasite was used only
at the end of the isolation procedure, with the pure compounds.
Using this strategy we arrived at a fraction containing two major
substances, one active (1) and the other inactive (2) in the TryR
assay (Table 1). Both compounds were, however, active against L.
amazonensis, showing EC50 values of 1.7 mM and 4.1 mM,
respectively (Figure 3).
After detailed analysis of the ESI-MS and NMR spectra, and
comparison of our data with those published in the literature [28],
compounds 1 and 2 were identified as cochlioquinone A and
isocochlioquinone, respectively (Figure 5). However, slightly
different interpretation of some NMR signals, as compared with
those described by Miyagawa [28], are noteworthy: a) the
hydrogen at C-5 in both compounds (Table 2 and Table 3–
position 5) couples with the three hydrogen atoms bound to C-27
and with the hydrogen at C-4, thus appearing as a double quartet,
with coupling constants J= 7.0 and 5.1 Hz, and not as quintet, as
described by Miyagawa; b) the two hydrogen atoms at C-2 in
compound 1 (Table 2–position 2) show distinct signals centered at
1.45 d and 1.08 d and not one centered at 1.35 d; c) the same is
true for compound 2 (Table 3–position 2), where the correspond-
ing signals are observed at 1.45 and 1.08 d and not only at 1.25 d,
and finally; d) the two hydrogen atoms at C-20 in compound 2
(Table 3–position 20) resonate at 1.46 d and 1.74 d and not only at
1.60 d as described by those authors.
Table 4.
13C-NMR and DEPT spectral data of compounds 1
and 2 and comparison with literature data for Cochlioquinone
A and Isocochlioquinone.
Position Chemical shifts Mult
b Chemical shifts Mult
b
1
Cochlioquinone
A
a 2
Isocochlioquinone
A
a
1 11.1 11.4 CH3 11.1 11.4 CH3
2 25.2 26.4 CH2 24.2 26.5 CH2
3 36.4 36.2 CH 36.4 36.2 CH
4 79.9 78.2 CH 80.6 79.0 CH
5 32.7 34.6 CH 34.4 35.5 CH
6 148.1 148.3 qC 139.7 140.2 qC
7 181.6 181.5 qC 135.0 135.3 qC
8 151.4 151.5 qC 143.8 144.0 qC
9 119.1 119.0 qC 107.0 107.0 qC
10 188.9 188.5 qC 153.2 153.2 qC
11 134.3 133.6 CH 108.2 108.2 CH
12 63.1 63.0 CH 198.3 198.5 C
13 51.7 51.8 CH 60.4 60.5 CH
14 83.2 83.0 qC 83.5 83.3 qC
15 37.5 37.5 CH2 37.6 37.6 CH2
16 24.0 25.2 CH2 25.0 25.0 CH2
17 83.8 83.8 CH 83.6 83.6 CH
18 36.7 36.7 qC 35.5 35.6 qC
19 38.6 38.5 CH2 37.4 37.3 CH2
20 21.5 21.5 CH2 21.3 21.3 CH2
21 85.1 85.1 CH 85.4 85.5 CH
22 71.9 71.7 qC 71.9 72.0 qC
23 23.8 24.0 CH3 23.8 23.8 CH3
24 26.1 25.9 CH3 26.0 26.0 CH3
25 12.6 12.6 CH3 12.3 12.5 CH3
26 21.1 21.0 CH3 22.0 22.0 CH3
27 18.2 17.2 CH3 18.0 17.5 CH3
28 15.4 13.2 CH3 15.3 13.5 CH3
29 170.6 170.3 qC 170.8 170.5 qC
30 20.9 20.7 CH3 21.0 20.8 CH3
Spectra were recorded at 100 MHz in CDCl3.
adata from reference [28].
bthe multiplicities were deduced from DEPT experiments; qC means quaternary
carbon.
doi:10.1371/journal.pntd.0000348.t004
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fungi from different genera, including Cochliobolus and Bipolaris
[29,30,31], Helminthosporium [32], Drechslera [33], and Stachybotrys
[30]. However, this is the first report on the leishmanicidal activity
of compounds belonging to this class of natural products.
It is known that quinonoid compounds with free positions in the
quinone ring are susceptible to nucleophilic attack by thiol groups
to form stable Michael addition products [34]. In this regard, after
1 was unequivocally identified as cochlioquinone A, its activity in
the Ellman’s-reagent-mediated TryR assay was questioned due to
the presence of a quinonoid ring in its structure. Thus, rather than
directly inhibiting the enzyme in the assay, cochlioquinone A
could be capturing the reduced substrate resulting in the
interruption of the chemical reduction of Ellman’s reagent
(Figure 6). To confirm this possibility, we performed the assay
using the classical protocol based on the measurement of NADPH
consumption [35] while using an excess trypanothione (100 mM)
in comparison to cochlioquinone A (50 mM). Indeed, under these
conditions no inhibition of the enzyme activity could be observed
(data not shown).
In view of the above results, we can conclude that cochlioqui-
none A and isocochlioquinone A are exerting their leishmanicidal
effect by hitting targets other than TryR within the parasite. A
literature search disclosed the following information: a) cochlio-
quinone A is a competitive inhibitor of the ivermectin binding site
in Caenorhabdites elegans, with an inhibition constant of 30 mM [36];
b) ivermectin is also active in vivo against different species of
Leishmania [37,38]; c) the mode of action of ivermectin in
nematodes is related to its high affinity to glutamate-gated chloride
channels, causing an increase in the permeability of the cell
membrane to chloride ions [39]; d) the TDR database of potential
drug targets for NDTs (http://tdrtargets.org) reveals four genes of
L. major expressing putative chloride ions transporters
(LmjF01.0180, LmjF04.1000, LmjF32.3370, and LmjF33.1060);
e) at least three of these genes have orthologs in C. elegans
(C07H4.2, R07B7.1), while LmjF01.0180 has an ortholog also in
T. cruzi (Tc00.1047053504797.140). Based on these pieces of
information it is plausible to speculate that chloride ions
transporters may also serve as a target for cochlioquinone A and
related compounds in Leishmania and Trypanosoma. This hypothesis
needs further experimental evidences to be confirmed or refuted.
Concerning isocochlioquinone A, the literature [40] show that it
can inhibit the growth of the malaria-causing protozoan parasite
Plasmodium falciparum with IC50 values of 1.4 mgm L
21 for the K1
strain (resistant to chloroquine and pyrimethamine), and 3.3 mg
mL
21 for the NF 54 strain (susceptible to standard antimalarials).
These values are close to the EC50 shown against L. amazonensis in
the present work.
Figure 5. Chemical structures of compounds isolated from Cochliobolus sp. UFMGCB-555. The numbering in these structures follows that
used in [42].
doi:10.1371/journal.pntd.0000348.g005
Figure 6. (A) Schematic view of the chemical and enzymatic reactions involved in the TryR assay resulting in the reduction of the
Elmman’s reagent (DTNB) to the yellow-colored 2-nitro-5-thiobenzoic acid (TNB); (B) Same as above, showing the interference of
cochlioquinone A resulting in a false positive readout due to its reaction with the reduced form of trypanothione, interrupting the
chemical reduction of DTNB.
doi:10.1371/journal.pntd.0000348.g006
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indicate that 1 and 2 present some degree of selectivity, as they
were inactive in the assays with three human cancer cell lines
(Table 1) and five pathogenic microorganisms (data not shown)
used in this investigation. The low toxicity of 1 and 2 to
mammalian cell lines reported in this work is in agreement with
recently reported data showing that isocochlioquinone A has only
a small effect on HeLa and KB cells [29,41]. Another study [33]
showed that when cochlioquinone A was tested in vitro against
different kinases it showed selective activity against diacylglycerol
kinase, both in vitro and in whole cell assay employing BW5147 T
cell lymphoma lineage. Related compounds, such as cochlioqui-
none A1, exhibited selective toxicity towards bovine aortic
endothelial cell when compared with normal and cancer cell lines
[29] leading the authors to suggest that it may serve for developing
new therapeutic agents for angiogenesis-related diseases.
The activity in the low micro molecular range towards L.
amazonensis and the selectivity of 1 and 2 are reported here for the
first time and justify further investigations on compounds of this
class to assess their in vitro and in vivo effect on parasites of the
genera Leishmania and Trypanosoma. Finally, by disclosing the
leishmanicidal activity of two secondary metabolites from an
endophytic fungus, the present work reinforces the role of these
organisms as an important source of drug lead candidates for the
development of new chemotherapeutic agents for NTDs.
Supporting Information
Figure S1
1H and
13C NMR spectra of the isolated compounds.
Found at: doi:10.1371/journal.pntd.0000348.s001 (0.09 MB PDF)
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